Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 17/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324733 | 0.82 | FFAR2 (0.46) | FFAR2MAPT | |
| SCHEMBL324104 | 0.78 | FFAR2 (0.43) | FFAR2MAPT | |
| SCHEMBL17376531 | 0.74 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL18919264 | 0.74 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL18919260 | 0.71 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL17382200 | 0.68 | FFAR2 (1.00) | FFAR2 | |
| SCHEMBL324734 | 0.65 | KDM4E (0.44) | FFAR2 | |
| SCHEMBL15174484 | 0.64 | RAPGEF4 (0.57) | MAPT | |
| SCHEMBL27876881 | 0.63 | MAPT (0.47) | FFAR2MAPTTP53 | |
| SCHEMBL4649415 | 0.63 | ROCK1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | DPYD, DHFR, TYMP | FFAR2 4433/4885MAPT 2750/4885TP53 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.